Medicare IVIG Access Enhancement Act of 2025
- Bill Number
- H.R. 1143
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-02-07: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Last Updated
- 2025-04-28T20:26:36Z
AI-Generated Summary
Purpose of the Legislation
The Medicare IVIG Access Enhancement Act of 2025 aims to broaden Medicare coverage for the in-home administration of intravenous immune globulin (IVIG), a medication given through an IV to treat certain immune and neurological disorders. This expansion seeks to make treatment more accessible for patients by including additional medical conditions beyond the current scope.
Key Provisions
- Expanded Coverage for IVIG: Starting January 1, 2027, Medicare will cover in-home IVIG administration not only for primary immune deficiency diseases (PIDD, conditions where the immune system is weakened and cannot fight infections effectively) but also for chronic inflammatory demyelinating polyneuropathy (CIDP, a disorder causing nerve damage and muscle weakness) and multifocal motor neuropathy (MMN, a condition affecting motor nerves and leading to muscle weakness).
- Amendments to the Social Security Act:
- Updates Section 1861(s)(2)(Z) to include CIDP and MMN in the list of covered conditions for IVIG services.
- Updates Section 1861(zz) to extend eligibility for home infusion therapy to patients diagnosed with CIDP or MMN.
- Payment Flexibility: Amends Section 1842(o)(8) to allow the Secretary of Health and Human Services (through a public rulemaking process) to adjust Medicare payments for IVIG based on whether it treats PIDD or the new conditions (CIDP or MMN). This could account for differences in treatment needs or costs.
Significant Changes to Existing Law
- Extension of Benefits: Current Medicare law limits in-home IVIG coverage to PIDD only. This bill removes that limitation by adding CIDP and MMN, effective in 2027, making home-based treatment an option for more patients who previously might have needed hospital or clinic visits.
- Payment Adjustments: Introduces the ability to vary reimbursement rates for IVIG administration, which was not previously specified for these distinctions. This requires a formal notice-and-comment process (a public input period for proposed rules) before implementation.
Potential Impacts
- On Citizens: Medicare beneficiaries with CIDP or MMN (estimated to affect tens of thousands of people, often leading to disability) could gain easier access to convenient, home-based IVIG treatment, potentially reducing travel burdens, infection risks from clinics, and improving quality of life. However, it may increase out-of-pocket costs if payments vary.
- On Government Agencies: The Centers for Medicare & Medicaid Services (CMS) will need to update policies, conduct rulemaking, and manage expanded claims, which could raise program costs (IVIG is expensive, often thousands per dose). No direct impact on international relations.
- Broader Healthcare System: May encourage more home health services, easing pressure on hospitals, but could strain budgets if utilization grows.
Main Stakeholders Affected
- Patients: Primarily Medicare enrollees (typically those 65+ or with disabilities) diagnosed with PIDD, CIDP, or MMN, who stand to benefit from expanded home treatment options.
- Healthcare Providers: Physicians, nurses, and home infusion companies that administer IVIG, as they may see increased reimbursements and demand.
- Pharmaceutical Industry: Manufacturers of IVIG drugs, who could experience higher demand and sales under Medicare.
- Government: CMS and the Department of Health and Human Services, responsible for implementation and oversight.
- Insurers and Taxpayers: Indirectly affected through potential rises in Medicare spending, funded by premiums and taxes.
Notable Legal, Constitutional, or Political Implications
- Legal: The bill relies on existing Medicare authority under the Social Security Act, with no new funding mandated (changes would use current appropriations). The rulemaking requirement ensures transparency and public input, aligning with administrative law standards. It could face challenges if payment variances lead to disparities in access.
- Constitutional: No apparent issues; it expands benefits under Congress's spending power without infringing on individual rights.
- Political: Represents a bipartisan effort (introduced by representatives from both parties) to enhance healthcare access for chronic conditions, potentially setting a precedent for future Medicare expansions. It may spark debates on program costs versus patient benefits in budget discussions.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (1)
Recent Actions
- 2025-02-07: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-02-07: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-02-07: Introduced in House
- 2025-02-07: Introduced in House
Bill Versions
- Medicare IVIG Access Enhancement Act of 2025 — issued 2025-02-07 — PDF (2 pages)